Future studies using a larger cohort of individuals with STXBP2 mutations will determine whether the reduction in STXBP1 protein levels in our STXBP2-deficient FHL case is a more general phenomenon, and will help to unravel the complexity of CL secretory machinery. This evidence concerns the gene STXBP2 and hemophagocytic syndrome.